Browsing Tag
MIQNAF
3 posts
Wockhardt delivers strong FY25 EBITDA, but net loss persists amid US restructuring drag
Wockhardt posts a 67% EBITDA jump in FY25, but Q4 PAT remains negative. Find out how novel antibiotics like Zaynich and Miqnaf are shaping investor sentiment.
Wockhardt secures approval for Miqnaf: A breakthrough in pneumonia treatment
In a landmark decision addressing the global challenge of antibiotic resistance, the Indian drug regulator, Central Drugs Standard…
Wockhardt sees Q2 revenue surge, driven by antibiotic innovation and biosimilar expansion
Wockhardt Limited, a leading pharmaceutical and biotechnology company, released its second-quarter financial results for the fiscal year 2024-25,…